Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial evaluating ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions. Derived from pooled ...

Monthly IVIG reduced grade ≥2 infections from 100% pre-treatment to 33% post-treatment, yielding a 67% relative and absolute risk reduction with strong statistical significance. Baseline IgG and IgA ...

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that attack ...

Immunoglobulin G antibodies (IgB) play an important role as drivers of inflammation in infectious diseases and autoimmune diseases. However, if the same immunoglobulin antibodies from the blood plasma ...

Please provide your email address to receive an email when new articles are posted on . IV immunoglobulin supplementation reduced the risk for developing severe infections among those receiving ...

Intravenous immunoglobulin (IVIG) is donor-derived antibodies used in myasthenia gravis (MG) for fast symptom control. It’s used for flares, maintenance, bridging slower therapies, or pre-surgery ...

Please provide your email address to receive an email when new articles are posted on . Gammagard Liquid is an immune globulin infusion (human) 10% solution. It is the only IV-based immunoglobulin ...

ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.